GE HealthCare (GEHC) official guidance

| Adjusted ETR\* | 20.2% | 20.0% - 21.0% | Reaffirmed |

•Adjusted effective tax rate (ETR)\* in the range of 20.0% to 21.0%

•Adjusted effective tax rate (ETR)* in the range of 20.0% to 21.0%; unchanged

Our adjusted effective tax rate is expected to be in the range of 20%-21% for the full year.

Adjusted effective tax rate (ETR)* in the range of 20.0% to 21.0%

| Adjusted EPS\* | $4.59 | $4.80 - $5.00 4.6% - 9.0% | $4.95 - $5.05 7.9% - 10.1% |

We're maintaining our adjusted EPS guidance in the range of $4.80-$5, approximately 5%-9% growth year-over-year.

•Adjusted EPS\* in the range of $4.80 to $5.00, representing 4.6% to 9.0% growth year-over-year

We're also reducing our adjusted EPS guidance to a range of $4.80-$5.00 per share, which represents approximately 5%-9% growth year-over-year.

•Adjusted EPS* in the range of $4.80 to $5.00, representing 4.6% to 9.0% growth year-over-year; this compares to previous Adjusted EPS* guidance in the range of $4.95 to $5.15

On adjusted EPS, we expect to deliver a range of $4.95-$5.15, representing 8%-12% growth.

Adjusted EPS* in the range of $4.95 to $5.15, representing 7.9% to 12.3% growth year-over-year

| Free Cash Flow\* | $1.5B | ~$1.6B | $1.6B+ |

Free cash flow is expected to be approximately $1.6 billion in 2026.

•Free cash flow\* of approximately $1.6 billion

With the change in profit outlook, we now expect free cash flow of approximately $1.6 billion in 2026.

•Free cash flow* of approximately $1.6 billion, in-line with profit outlook; this compares to previous guidance of approximately $1.7 billion

Lastly, we anticipate free cash flow of approximately $1.7 billion for the full year, representing growth of 13.0%.

Free cash flow* of approximately $1.7 billion

| Adjusted EBIT Margin\* | 15.3% | 15.4% - 15.7% 10 - 40 bps | 15.5% - 15.7% 20 - 40 bps |

That gets us to a range of 15.4%-15.7%.

•Adjusted EBIT margin\* of 15.4% to 15.7%, reflecting an expansion of 10 bps to 40 bps year-over-year. Continue to expect approximately $250 million of inflation associated with memory chips, oil and freight and other components.

We now expect adjusted EBIT margin to be in the range of 15.4%-15.7%, reflecting expansion of 10-40 basis points year-over-year.

•Adjusted EBIT margin* of 15.4% to 15.7%, reflecting an expansion of 10 bps to 40 bps year-over-year; this compares to previous Adjusted EBIT margin* guidance of 15.8% to 16.1%

Adjusted EBIT is expected to be in the range of 15.8%-16.1%, reflecting 50 basis points-80 basis points of expansion...

Adjusted EBIT margin* of 15.8% to 16.1%, reflecting an expansion of 50 bps to 80 bps year-over-year

| Organic Revenue Growth\*(1) | 3.5% | 3.0% - 4.0% | ~4.0% |

•Organic revenue growth\* of 3.0% to 4.0% year-over-year

•Organic revenue growth* of 3.0% to 4.0% year-over-year; unchanged

For 2026, we expect organic revenue growth of 3%-4%. We've taken a prudent approach to this guidance, which reflects a healthy capital equipment environment and continued commercial execution while factoring in a cautious outlook on China.

Organic revenue growth* of 3.0% to 4.0% year-over-year

We remain confident in our medium-term target of $500 million or more in annual revenues by 2028.

We're encouraged by our trajectory, and this reinforces our confidence in our medium-term target of $500 million or more in annual revenue by 2028.

As I stated before, our confidence in our ability to deliver $500 million or more in Flyrcado revenue by year-end 2028 remains intact, and in the long run, we see a billion-dollar opportunity for this novel molecule.

This positions us really well on our midterm expectations for a half $500 million by 2028.

We're maintaining full year guidance. This reflects 3%-4% organic sales growth and 10 basis points to 40 basis points adjusted EBIT margin expansion.

We now expect adjusted EBIT margin to be in the range of 15.4%-15.7%, reflecting expansion of 10-40 basis points year-over-year.

Continue to expect approximately $250 million of inflation associated with memory chips, oil and freight and other components.

Related to adjusted EBIT, as noted earlier, we expect approximately $250 million of gross inflation impact for the full year.

We were intentional in setting a cautious outlook for 2026 and still expect the China sales to be down year-over-year.

Relative to foreign exchange, we expect a benefit to revenue of approximately 150 basis points for the year.